Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TENX
SELLTenax Therapeutics, Inc. · Healthcare · United States · $385M · Avg Vol: $23M/d
28
StockRankGet insider-trade alerts
Q
33
V
24
M
60
P/E (TTM)
—
ROE
-51.7%
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)+41.0%
SMA 50SMA 200
Close
$16.19
RSI (14)
42.6
52W High
$19.40
From 52W High
0.8%
SCORE BREAKDOWN
Quality
33
ROIC
-60.5%12.1
ROE
-51.7%18.1
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-18.0%20.8
Piotroski
111.4
Int. Cover
—N/A
D/E Ratio
0.00x97.8
Current Ratio
14.52x92.0
Value
24
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
6.4x21.1
P/S
—N/A
Div Yield
—N/A
Momentum
60
52W High %
83%75.8
RS 6M
2%75.1
SMA 50/200
1.10x82.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+2%23.0
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$385M
P/E (Forward)
-10.5x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TENX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TENX | Tenax Therapeutics, Inc.(you) | $385M | 28 | SELL |
| IPSC | Century Therapeutics, Inc. | $381M | 28 | SELL |
| AVIR | Atea Pharmaceuticals, Inc. | $379M | 29 | SELL |
| PALI | Palisade Bio, Inc. | $339M | 29 | SELL |
| PRTC.L | PureTech Health plc | $421M | 26 | SELL |
| SGMT | Sagimet Biosciences Inc. | $437M | 30 | SELL |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $308M | 28 | SELL |
| BNTC | Benitec Biopharma Inc. | $394M | 24 | SELL |
| ENTA | Enanta Pharmaceuticals, Inc. | $372M | 23 | SELL |
| CCCC | C4 Therapeutics, Inc. | $376M | 34 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%